These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 15665549

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR, Romero B, Fernandez-Carbonero E, Sánchez-Casado E, Cubero JJ.
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [Abstract] [Full Text] [Related]

  • 23. Effect of the angiotensin converting enzyme inhibitor, captopril, on proteinuria in chronic glomerular disease.
    Masunaga Y, Tabei K, Takeda S, Ando Y, Kusano E, Asano Y.
    Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):961-6. PubMed ID: 8255007
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effects of captopril on urinary excretion of albumin and prostaglandins in patients with diabetic nephropathy.
    Tajiri Y, Umeda F, Inoguchi T, Kunisaki M, Nawata H, Ninomiya H, Asano T.
    Diabetes Res; 1990 Mar; 13(3):145-50. PubMed ID: 2091882
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.
    McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G.
    Am J Kidney Dis; 2008 Sep; 52(3):454-63. PubMed ID: 18433957
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
    Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM.
    Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.
    Navarro-González JF, Muros M, Mora-Fernández C, Herrera H, Meneses B, García J.
    J Diabetes Complications; 2011 Apr; 25(5):314-9. PubMed ID: 21144773
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease.
    Krairittichai U, Mahannopkul R, Bunnag S.
    J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S41-7. PubMed ID: 22619886
    [Abstract] [Full Text] [Related]

  • 35. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
    Erman A, Boner G, van Dijk DJ.
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):365-8. PubMed ID: 11967825
    [Abstract] [Full Text] [Related]

  • 36. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial.
    Rodriguez-Morán M, González-González G, Bermúdez-Barba MV, Medina de la Garza CE, Tamez-Pérez HE, Martínez-Martínez FJ, Guerrero-Romero F.
    Clin Nephrol; 2006 Jul; 66(1):3-10. PubMed ID: 16878429
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.